Please assess the completion status of the following clinical trial:

Trial Title: Pediatric Study to Evaluate Risk of Developing Essential Fatty Acid Deficiency When Receiving Clinolipid or Standard-of-Care Lipid Emulsion

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients and/or their legal representative must be able to understand the study and voluntarily sign the ICF~2. Patients age \<18 years~3. Patients who are able to adhere to protocol requirements~4. Patients who are expected to require PN for at least 7 days~5. Premature infants (\<36 weeks of gestation) require at least 80% PN to meet nutrition requirements at study entry; full term infants and children require at least 70% PN to meet nutrition requirements at study entry~Exclusion Criteria:~1. Patients who are not expected to survive hospitalization or with a severe illness with foreseeable intercurrent events that could jeopardize the patient's participation in the study~2. Patients with a known hypersensitivity to lipid emulsion, egg or soybean proteins, or any of the active substances, excipients, or components of the container~3. Patients with a diagnosis of shock, renal failure requiring dialysis, or severe metabolic acidosis (eg, pH \<7.10, serum bicarbonate level ≤15 mEq/L , and/or an Anion Gap \>16 mEq/L)~4. Patients with hemodynamic instability as judged by the Investigator~5. Patients with uncorrected metabolic disorders (eg, diabetes) or liver disease including cholestasis~6. Patients with severe hyperlipidemia or severe disorders of lipid metabolism characterized by hypertriglyceridemia (triglyceride \>400 mg/dL)~7. Patients who are unable to tolerate the necessary laboratory monitoring~8. Patients who have a new and active infection (as assessed by the investigator) at time of initiation of study treatment~9. Patients who are enrolled in another clinical trial involving an investigational agent~10. Patients who were treated with IV lipids within 48 hours of randomization into the study

- Gender: ALL
- Minimum Age: None
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Clinolipid (lipid injectable emulsion, USP) 20% (Type: EXPERIMENTAL): Dosing schedule based on subject's age, weight, and medical condition and as per ESPEN-ESPHAN guidelines.
- Intralipid 20% (lipid injectable emulsion, USP) (Type: ACTIVE_COMPARATOR): Dosing schedule based on subject's age, weight, and medical condition and as per ESPEN-ESPHAN guidelines.

Based on this trial design, predict the completion outcome and termination type (if applicable).